{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T09:12:08Z","timestamp":1790759528499,"version":"4.1.0"},"reference-count":100,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,10,3]],"date-time":"2022-10-03T00:00:00Z","timestamp":1664755200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002996","name":"Hartstichting","doi-asserted-by":"publisher","award":["03-005-2021-T00"],"award-info":[{"award-number":["03-005-2021-T00"]}],"id":[{"id":"10.13039\/501100002996","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001721","name":"Rijksuniversiteit Groningen","doi-asserted-by":"publisher","award":["MA 20-04"],"award-info":[{"award-number":["MA 20-04"]}],"id":[{"id":"10.13039\/501100001721","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Immune checkpoint inhibitors (ICI) are monoclonal antibodies which bind to immune checkpoints (IC) and their ligands to prevent inhibition of T-cell activation by tumor cells. Currently, multiple ICI are approved targeting Cytotoxic T-lymphocyte antigen 4 (CTLA-4), Programmed Death Protein 1 (PD-1) and its ligand PD-L1, and Lymphocyte-activation gene 3 (LAG-3). This therapy has provided potent anti-tumor effects and improved prognosis for many cancer patients. However, due to systemic effects, patients can develop immune related adverse events (irAE), including possible life threatening cardiovascular irAE, like atherosclerosis, myocarditis and cardiomyopathy. Inhibition of vascular IC is associated with increased atherosclerotic burden and plaque instability. IC protect against atherosclerosis by inhibiting T-cell activity and cytokine production, promoting regulatory T-cell differentiation and inducing T-cell exhaustion. In addition, PD-L1 on endothelial cells might promote plaque stability by reducing apoptosis and increasing expression of tight junction molecules. In the heart, IC downregulate the immune response to protect against cardiac injury by reducing T-cell activity and migration. Here, inhibition of IC could induce life-threatening T-cell-mediated-myocarditis. One proposed purpose behind lymphocyte infiltration is reaction to cardiac antigens, caused by decreased self-tolerance, and thereby increased autoimmunity because of IC inhibition. In addition, there are several reports of ICI-mediated cardiomyopathy with immunoglobulin G expression on cardiomyocytes, indicating an autoimmune response. IC are mostly known due to their cardiotoxicity. However, t his review compiles current knowledge on mechanisms behind IC function in cardiovascular disease with the aim of providing an overview of possible therapeutic targets in prevention or treatment of cardiovascular irAEs.<\/jats:p>","DOI":"10.3389\/fphar.2022.989431","type":"journal-article","created":{"date-parts":[[2022,10,3]],"date-time":"2022-10-03T09:53:20Z","timestamp":1664790800000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":31,"title":["The role of immune checkpoints in cardiovascular disease"],"prefix":"10.3389","volume":"13","author":[{"given":"Laura I.","family":"Yousif","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anniek A.","family":"Tanja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf A.","family":"de Boer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arco J.","family":"Teske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wouter C.","family":"Meijers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,10,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/NM1343","article-title":"Natural regulatory T cells control the development of atherosclerosis in mice","volume":"12","author":"Ait-Oufella","year":"2006","journal-title":"Nat. Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1161\/01.atv.11.5.1223","article-title":"Cytokines and growth factors positively and negatively regulate interstitial collagen gene expression in human vascular smooth muscle cells","volume":"11","author":"Amento","year":"1991","journal-title":"Arterioscler. Thromb."},{"key":"B3","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/J.IMMUNI.2016.05.001","article-title":"Lag-3, Tim-3, and TIGIT co-inhibitory receptors with specialized functions in immune regulation","volume":"44","author":"Anderson","year":"2016","journal-title":"Immunity"},{"key":"B4","unstructured":"Cardiovascular complications of immune checkpoint inhibitors, TILs and CAR T-cell therapies\n            AndresM.\n            RamalingamS.\n          2019"},{"key":"B5","doi-asserted-by":"publisher","first-page":"3635","DOI":"10.1182\/BLOOD-2007-11-123141","article-title":"B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells","volume":"111","author":"Azuma","year":"2008","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-1315661\/v1","article-title":"Cytotoxic T cells specic for alpha-myosin drive immunotherapy related myocarditis","author":"Balko","year":"2022"},{"key":"B7","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/J.JTHO.2020.11.002","article-title":"Cardiac toxicity of thoracic radiotherapy: Existing evidence and future directions","volume":"16","author":"Banfill","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"e003551","DOI":"10.1136\/jitc-2021-003551","article-title":"Potential therapies for immune-related adverse events associated with immune checkpoint inhibition: From monoclonal antibodies to kinase inhibition","volume":"10","author":"Berg","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40425-016-0139-8","article-title":"Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody","volume":"4","author":"Bilen","year":"2016","journal-title":"J. Immunother. Cancer"},{"key":"B10","unstructured":"Undefined Cytotoxic T-lymphocyte\u2013associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancernih.gov\n            BlansfieldJ.\n            BeckK.\n            TranK.\n            ofJ. Y.-J.\n          2005"},{"key":"B11","doi-asserted-by":"publisher","first-page":"OF3","DOI":"10.1158\/2159-8290.CD-NB2017-167","article-title":"Blocking Ido1 Helps Shrink bladder","volume":"8","year":"2018","journal-title":"Cancer Discov."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1161\/ATVBAHA.111.224709","article-title":"Impairment of the programmed cell death-1 pathway increases atherosclerotic lesion development and inflammation","volume":"31","author":"Bu","year":"2011","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/COC.0000000000000239","article-title":"CTLA-4 and PD-1 pathways: Similarities, differences, and implications of their inhibition","volume":"39","author":"Buchbinder","year":"2016","journal-title":"Am. J. Clin. Oncol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"e001887","DOI":"10.1136\/JITC-2020-001887","article-title":"Original research: Intensified immunosuppressive therapy in patients with immune checkpoint inhibitor-induced myocarditis","volume":"8","author":"Cautela","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"B15","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1200\/JOP.18.00208","article-title":"Myocarditis with radiotherapy and immunotherapy in multiple myeloma","volume":"14","author":"Chang","year":"2018","journal-title":"J. Oncol. Pract."},{"key":"B16","doi-asserted-by":"publisher","first-page":"2729","DOI":"10.1073\/PNAS.0813175106","article-title":"Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-gamma levels in both nonmalignant and malignant prostate tissues","volume":"106","author":"Chen","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B17","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/nri3405","article-title":"Molecular mechanisms of T cell co-stimulation and co-inhibition","volume":"13","author":"Chen","year":"2013","journal-title":"Nat. Rev. Immunol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/J.ATHEROSCLEROSIS.2015.11.002","article-title":"Human umbilical vein endothelial cells promote the inhibitory activation of CD4+CD25+Foxp3+ regulatory T cells via PD-L1","volume":"244","author":"Chen","year":"2016","journal-title":"Atherosclerosis"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.3892\/or.2017.5399","article-title":"The JAK\/STAT pathway is involved in the upregulation of PD-L1 expression in pancreatic cancer cell lines","volume":"37","author":"Doi","year":"2017","journal-title":"Oncol. Rep."},{"key":"B20","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1161\/CIRCULATIONAHA.120.049981","article-title":"Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque","volume":"142","author":"Drobni","year":"2020","journal-title":"Circulation"},{"key":"B21","doi-asserted-by":"publisher","first-page":"4712","DOI":"10.1038\/S41467-019-12628-1","article-title":"Targeting the mTOR pathway uncouples the efficacy and toxicity of PD-1 blockade in renal transplantation","volume":"10","author":"Esfahani","year":"2019","journal-title":"Nat. Commun."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1016\/J.IJCARD.2012.12.085","article-title":"T-cell co-stimulation by CD28\u2013CD80\/86 and its negative regulator CTLA-4 strongly influence accelerated atherosclerosis development","volume":"168","author":"Ewing","year":"2013","journal-title":"Int. J. Cardiol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1038\/ni1003","article-title":"Modulation of tryptophan catabolism by regulatory T cells","volume":"4","author":"Fallarino","year":"2003","journal-title":"Nat. Immunol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1038\/S41591-019-0590-4","article-title":"Single-cell immune landscape of human atherosclerotic plaques","volume":"25","author":"Fernandez","year":"2019","journal-title":"Nat. Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/S0021-9150(99)00011-8","article-title":"Cytokine expression in advanced human atherosclerotic plaques: Dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines","volume":"145","author":"Frosteg\u00e5rd","year":"1999","journal-title":"Atherosclerosis"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1016\/J.CELREP.2017.07.075","article-title":"PDL1 signals through conserved sequence motifs to overcome interferon-mediated cytotoxicity","volume":"20","author":"Gato-Ca\u00f1as","year":"2017","journal-title":"Cell. Rep."},{"key":"B27","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1093\/INTIMM\/DXQ049","article-title":"PD-L1 and PD-L2 differ in their molecular mechanisms of interaction with PD-1","volume":"22","author":"Ghiotto","year":"2010","journal-title":"Int. Immunol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"88628","DOI":"10.1172\/JCI.INSIGHT.88628","article-title":"Lymphocyte activation gene 3 and coronary artery disease","volume":"1","author":"Golden","year":"2016","journal-title":"JCI Insight"},{"key":"B29","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1172\/JCI31344","article-title":"Proatherogenic immune responses are regulated by the PD-1\/PD-L pathway in mice","volume":"117","author":"Gotsman","year":"2007","journal-title":"J. Clin. Investig."},{"key":"B30","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1161\/CIRCRESAHA.107.155838","article-title":"Targeting interferon-\u03b3 to treat atherosclerosis","volume":"101","author":"Gotsman","year":"2007","journal-title":"Circ. Res."},{"key":"B31","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1161\/CIRCULATIONAHA.107.709360","article-title":"Endothelial programmed death-1 ligand 1 (PD-L1) regulates CD8+ T-cell mediated injury in the heart","volume":"116","author":"Grabie","year":"2007","journal-title":"Circulation"},{"key":"B32","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1093\/CVR\/CVZ025","article-title":"T cell checkpoint regulators in the heart","volume":"115","author":"Grabie","year":"2019","journal-title":"Cardiovasc. Res."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1038\/ni846","article-title":"CTLA-4\u2013Ig regulates tryptophan catabolism in vivo","volume":"3","author":"Grohmann","year":"2002","journal-title":"Nat. Immunol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"5173","DOI":"10.4049\/JIMMUNOL.1002050","article-title":"MHC class II engagement by its ligand LAG-3 (CD223) contributes to melanoma resistance to apoptosis","volume":"186","author":"Hemon","year":"2011","journal-title":"J. Immunol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s13045-016-0343-5","article-title":"Targeting of PI3K\/AKT\/mTOR pathway to inhibit T cell activation and prevent graft-versus-host disease development","volume":"9","author":"Herrero-S\u00e1nchez","year":"2016","journal-title":"J. Hematol. Oncol."},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.21203\/RS.3.RS-1749981\/V2","article-title":"Serum cholesterol-riched apolipoprotein-B (apoB) containing lipoproteins predict the response to immune checkpoints inhibitors (ICIs) in non-small cell lung cancer (nsclc) : A retrospective analysis","author":"Hu","year":"2022"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.3389\/fcvm.2022.912329","article-title":"Clinical manifestations, monitoring, and prognosis: A review of cardiotoxicity after antitumor strategy","volume":"9","author":"Huang","year":"2022","journal-title":"Front. Cardiovasc. Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"230ra45","DOI":"10.1126\/SCITRANSLMED.3008002","article-title":"Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody","volume":"6","author":"Iwama","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"B39","doi-asserted-by":"publisher","first-page":"4735","DOI":"10.1158\/1078-0432.ccr-18-4083","article-title":"Myocarditis in cynomolgus monkeys following treatment with immune checkpoint inhibitors","volume":"25","author":"Ji","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"B41","doi-asserted-by":"publisher","first-page":"321","DOI":"10.4331\/WJBC.V5.I3.321","article-title":"Mnk kinase pathway: Cellular functions and biological outcomes","volume":"5","author":"Joshi","year":"2014","journal-title":"World J. Biol. Chem."},{"key":"B42","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1158\/2326-6066.CIR-14-0150","article-title":"Galectin-3 shapes antitumor immune responses by suppressing CD8+ T cells via LAG-3 and inhibiting expansion of plasmacytoid dendritic cells","volume":"3","author":"Kouo","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"B43","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1136\/ANNRHEUMDIS-2013-203756","article-title":"The JAK inhibitor, tofacitinib, reduces the T cell stimulatory capacity of human monocyte-derived dendritic cells","volume":"73","author":"Kubo","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"B44","doi-asserted-by":"publisher","first-page":"759972","DOI":"10.3389\/FCVM.2021.759972","article-title":"Myocardial PD-L1 expression in patients with ischemic and non-ischemic heart failure","author":"Kushnareva","year":"2022","journal-title":"Front. Cardiovasc. Med."},{"key":"B45","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"B46","doi-asserted-by":"publisher","first-page":"682262","DOI":"10.3389\/FIMMU.2021.682262","article-title":"Immune myocarditis overlapping with myasthenia gravis due to anti-PD-1 treatment for a chordoma patient: A case report and literature review","volume":"12","author":"Liang","year":"2021","journal-title":"Front. Immunol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1158\/2326-6066.CIR-19-0702","article-title":"Fatty acid oxidation controls CD8+Tissue-resident memory t-cell survival in gastric adenocarcinoma","volume":"8","author":"Lin","year":"2020","journal-title":"Cancer Immunol. Res."},{"key":"B48","doi-asserted-by":"publisher","first-page":"9503","DOI":"10.1200\/JCO.2021.39.15_suppl.9503.39","article-title":"Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: Primary phase III results from RELATIVITY-047 (CA224-047)","author":"Lipson","year":"2021"},{"key":"B49","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1177\/1078155220947141","article-title":"Tofacitinib for treatment in immune-mediated myocarditis: The first reported cases","volume":"27","author":"Liu","year":"2020","journal-title":"J. Oncol. Pharm. Pract."},{"key":"B50","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1038\/NI939","article-title":"The inhibitory function of B7 costimulators in T cell responses to foreign and self-antigens","volume":"4","author":"Lohr","year":"2003","journal-title":"Nat. Immunol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/S1470-2045(19)30274-8","article-title":"Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301\/KEYNOTE-252): phase 3, randomised, double-blind study","volume":"20","author":"Long","year":"2019","journal-title":"Lancet. Oncol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.4049\/jimmunol.1800271","article-title":"Type 1 IFN and PD-L1 coordinate lymphatic endothelial cell expansion and contraction during an inflammatory immune response","volume":"201","author":"Lucas","year":"2018","journal-title":"J. Immunol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"ehac244","DOI":"10.1093\/EURHEARTJ\/EHAC244","article-title":"2022 ESC guidelines on cardio-oncology developed in collaboration with the European hematology association (EHA), the European society for therapeutic radiology and oncology (ESTRO) and the international cardio-oncology society (IC-OS).","author":"Lyon","year":"2022","journal-title":"Eur. Heart J."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/J.JACC.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"446","DOI":"10.3390\/CELLS10020446","article-title":"ApoB-specific CD4+ T cells in mouse and human atherosclerosis","volume":"10","author":"Marchini","year":"2021","journal-title":"Cells"},{"key":"B56","doi-asserted-by":"publisher","first-page":"e318","DOI":"10.3324\/HAEMATOL.2017.185777","article-title":"Anti-PD1 associated fulminant myocarditis after a single pembrolizumab dose: The role of occult pre-existing autoimmunity","volume":"103","author":"Martinez-Calle","year":"2018","journal-title":"Haematologica"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1161\/ATVBAHA.115.306848","article-title":"Overexpression of cytotoxic T-lymphocyte-associated antigen-4 prevents atherosclerosis in mice","volume":"36","author":"Matsumoto","year":"2016","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s40959-021-00114-x","article-title":"Immune checkpoint inhibitor-induced myocarditis in cancer patients: A case report and review of reported cases","volume":"7","author":"Matzen","year":"2021","journal-title":"Cardio-Oncology"},{"key":"B59","doi-asserted-by":"publisher","first-page":"3581","DOI":"10.4049\/jimmunol.169.7.3581","article-title":"B7-H1 is expressed by human endothelial cells and suppresses T cell cytokine synthesis.","volume":"169","author":"Mazanet","year":"2022","journal-title":"J. Immunol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"e0213025","DOI":"10.1371\/JOURNAL.PONE.0213025","article-title":"Keratin 8 is a potential self-antigen in the coronary artery disease immunopeptidome: A translational approach","volume":"14","author":"Mihailovic","year":"","journal-title":"PLoS One"},{"key":"B61","doi-asserted-by":"publisher","first-page":"e0213025","DOI":"10.1371\/JOURNAL.PONE.0213025","article-title":"Keratin 8 is a potential self-antigen in the coronary artery disease immunopeptidome: A translational approach","volume":"14","author":"Mihailovic","year":"","journal-title":"PLoS One"},{"key":"B62","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1126\/science.291.5502.319","article-title":"Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice","volume":"291","author":"Nishimura","year":"2001","journal-title":"Science"},{"key":"B63","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1084\/JEM.20100466","article-title":"PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice","volume":"208","author":"Okazaki","year":"2011","journal-title":"J. Exp. Med."},{"key":"B64","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1038\/NM955","article-title":"Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice","volume":"9","author":"Okazaki","year":"2003","journal-title":"Nat. Med."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1038\/NI1124","article-title":"CD28 induces immunostimulatory signals in dendritic cells via CD80 and CD86","volume":"5","author":"Orabona","year":"2004","journal-title":"Nat. Immunol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1016\/J.AMJCARD.2020.02.016","article-title":"Cardiovascular health and outcomes in cancer patients receiving immune checkpoint inhibitors","volume":"125","author":"Oren","year":"2020","journal-title":"Am. J. Cardiol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1200\/JCO.2017.76.9901","article-title":"Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient\/microsatellite instability-high metastatic colorectal cancer","volume":"36","author":"Overman","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"9543","DOI":"10.1128\/MCB.25.21.9543-9553.2005","article-title":"CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms","volume":"25","author":"Parry","year":"2005","journal-title":"Mol. Cell. Biol."},{"key":"B69","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.3390\/CELLS9091987","article-title":"Antibody-mediated inhibition of CTLA4 aggravates atherosclerotic plaque inflammation and progression in hyperlipidemic mice","volume":"9","author":"Poels","year":"2020","journal-title":"Cells"},{"key":"B70","doi-asserted-by":"publisher","first-page":"721333","DOI":"10.3389\/FCVM.2021.721333","article-title":"Immune checkpoint inhibitors mediated lymphocytic and giant cell myocarditis: Uncovering etiological mechanisms","author":"Rikhi","year":"2021","journal-title":"Front. Cardiovasc. Med."},{"key":"B71","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1172\/JCI18607","article-title":"Disruption of TGF-\u03b2 signaling in T cells accelerates atherosclerosis","volume":"112","author":"Robertson","year":"2003","journal-title":"J. Clin. Investig."},{"key":"B72","doi-asserted-by":"publisher","first-page":"3117","DOI":"10.1002\/EJI.200324270","article-title":"Endothelial expression of PD-L1 and PD-L2 down-regulates CD8+ T cell activation and cytolysis","volume":"33","author":"Rodig","year":"2003","journal-title":"Eur. J. Immunol."},{"key":"B73","doi-asserted-by":"publisher","first-page":"540","DOI":"10.3390\/VACCINES10040540","article-title":"Exploring the mechanisms underlying the cardiotoxic effects of immune checkpoint inhibitor therapies","volume":"10","author":"Ronen","year":"2022","journal-title":"Vaccines"},{"key":"B74","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1002\/EJHF.2289","article-title":"Cardiotoxicity associated with immune checkpoint inhibitor therapy: A meta-analysis","volume":"23","author":"Rubio-Infante","year":"2021","journal-title":"Eur. J. Heart Fail."},{"key":"B75","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/J.1600-065X.2009.00770.X","article-title":"CD28 and CTLA-4 coreceptor expression and signal transduction","volume":"229","author":"Rudd","year":"2009","journal-title":"Immunol. Rev."},{"key":"B76","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1038\/ejhg.2010.3","article-title":"Evidence for CTLA4 as a susceptibility gene for dilated cardiomyopathy","volume":"18","author":"Ruppert","year":"2010","journal-title":"Eur. J. Hum. Genet."},{"key":"B77","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/S41569-020-0352-5","article-title":"T cell subsets and functions in atherosclerosis","volume":"17","author":"Saigusa","year":"2020","journal-title":"Nat. Rev. Cardiol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/s1470-2045(18)30608-9","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: An observational, retrospective, pharmacovigilance study","volume":"19","author":"Salem","year":"2018","journal-title":"Lancet. Oncol."},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1093\/EHJCI\/EHAA946.3625","article-title":"Novel mechanism in cardiac injury: Immune checkpoints","volume":"41","author":"Screever","year":"2020","journal-title":"Eur. Heart J."},{"key":"B80","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/J.LUNGCAN.2016.06.025","article-title":"Drug-induced myocarditis after nivolumab treatment in a patient with PDL1- negative squamous cell carcinoma of the lung","volume":"99","author":"Semper","year":"2016","journal-title":"Lung Cancer"},{"key":"B81","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1126\/science.aaa8172","article-title":"The future of immune checkpoint therapy","volume":"348","author":"Sharma","year":"2015","journal-title":"Science"},{"key":"B82","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1136\/HEARTJNL-2020-318083","article-title":"Cardiotoxicities of novel cancer immunotherapies","volume":"107","author":"Stein-Merlob","year":"2021","journal-title":"Heart"},{"key":"B83","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s13045-021-01080-8","article-title":"Indoleamine 2, 3-dioxygenase 1 (Ido1) inhibitors in clinical trials for cancer immunotherapy","volume":"14","author":"Tang","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"B85","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.3390\/IJMS21072399","article-title":"Programmed cell death-1: Programmed cell death-ligand 1 interaction protects human cardiomyocytes against T-cell mediated inflammation and apoptosis response in vitro","volume":"21","author":"Tay","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"B86","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1002\/ART.41068","article-title":"Safety and efficacy of immune checkpoint inhibitors in patients with cancer and preexisting autoimmune disease: A nationwide, multicenter cohort study","volume":"71","author":"Tison","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"B87","doi-asserted-by":"publisher","first-page":"8159","DOI":"10.3390\/IJMS21218159","article-title":"Delicate role of PD-L1\/PD-1 Axis in blood vessel inflammatory diseases: Current insight and future significance","volume":"202021","author":"Veluswamy","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"B88","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/J.JACC.2021.11.048","article-title":"Immune checkpoint therapies and atherosclerosis: Mechanisms and clinical implications: JACC state-of-the-art review","volume":"79","author":"Vuong","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"key":"B89","doi-asserted-by":"publisher","first-page":"12624","DOI":"10.1038\/ncomms12624","article-title":"Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma","volume":"7","author":"Wallin","year":"2016","journal-title":"Nat. Commun."},{"key":"B90","doi-asserted-by":"publisher","first-page":"770631","DOI":"10.3389\/FPHAR.2021.770631","article-title":"Case series of steroid-resistant immune checkpoint inhibitor associated myocarditis: A comparative analysis of corticosteroid and tofacitinib treatment","volume":"12","author":"Wang","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B91","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1001\/JAMAONCOL.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: A systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol."},{"key":"B92","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/J.CELL.2018.11.010","article-title":"Fibrinogen-like protein 1 is a major immune inhibitory ligand of LAG3","volume":"176","author":"Wang","year":"2019","journal-title":"Cell."},{"key":"B93","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1158\/2159-8290.cd-20-0856","article-title":"A genetic mouse model recapitulates immune checkpoint inhibitor\u2013associated myocarditis and supports a mechanism-based therapeutic intervention","volume":"11","author":"Wei","year":"2021","journal-title":"Cancer Discov."},{"key":"B94","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/nri3862","article-title":"Molecular and cellular insights into T cell exhaustion","volume":"15","author":"Wherry","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"B95","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1002\/eji.202048747","article-title":"Combined anti-PD-1 and anti-CTLA-4 checkpoint blockade: Treatment of melanoma and immune mechanisms of action","volume":"51","author":"Willsmore","year":"2021","journal-title":"Eur. J. Immunol."},{"key":"B96","doi-asserted-by":"publisher","first-page":"101383","DOI":"10.1016\/J.TRANON.2022.101383","article-title":"Cardiovascular toxicity following immune checkpoint inhibitors: A systematic review and meta-analysis","volume":"19","author":"Xavier","year":"2022","journal-title":"Transl. Oncol."},{"key":"B97","doi-asserted-by":"publisher","first-page":"3418","DOI":"10.1158\/0008-5472.CAN-13-2690","article-title":"LSECtin expressed on melanoma cells promotes tumor progression by inhibiting antitumor T-cell responses","volume":"74","author":"Xu","year":"2014","journal-title":"Cancer Res."},{"key":"B98","doi-asserted-by":"publisher","first-page":"4179","DOI":"10.1172\/JCI91258","article-title":"MNK1\/2 inhibition limits oncogenicity and metastasis of KIT-mutant melanoma","volume":"127","author":"Zhan","year":"2017","journal-title":"J. Clin. Investig."},{"key":"B99","doi-asserted-by":"publisher","first-page":"eaah4569","DOI":"10.1126\/SCIIMMUNOL.AAH4569","article-title":"LAG-3 limits regulatory T cell proliferation and function in autoimmune diabetes","volume":"2","author":"Zhang","year":"2017","journal-title":"Sci. Immunol."},{"key":"B100","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/J.IMMUNI.2011.04.008","article-title":"Cell surface signaling molecules in the control of immune responses: A tide model","volume":"34","author":"Zhu","year":"2011","journal-title":"Immunity"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.989431\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,3]],"date-time":"2022-10-03T09:53:24Z","timestamp":1664790804000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.989431\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,3]]},"references-count":100,"alternative-id":["10.3389\/fphar.2022.989431"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.989431","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,3]]},"article-number":"989431"}}